All canine diagnoses

Your dog was diagnosed with Renal Carcinoma. Uncommon (~1% of canine tumours). Renal cell carcinoma is the most common primary renal malignancy. Often unilateral. May be incidental finding on imaging. German Shepherds at hereditary risk (BHD gene mutation — renal cystadenocarcinoma). Compare 2 treatment options for dogs including Nephrectomy, Palliative / Supportive Care — with survival times, costs, and what to expect during treatment.

🐕

Renal Carcinoma

BreedsGerman Shepherd (hereditary cystadenocarcinoma — BHD gene)No other strong breed predispositions
canine

Epithelial

About This Cancer

Renal cell carcinoma is a cancer arising from the epithelial cells of the kidney tubules — the microscopic structures responsible for filtering blood and producing urine. It is the most common primary malignant kidney tumour in dogs, though it remains uncommon overall. The tumour is usually unilateral (affecting one kidney), and surgical removal of the affected kidney (nephrectomy) can be curative if the cancer has not spread. Many cases are found incidentally during abdominal imaging for other reasons. German Shepherd Dogs have a hereditary predisposition through a specific gene mutation (in the BHD/folliculin gene) that causes a distinct form called renal cystadenocarcinoma. Prognosis depends on whether the cancer has spread at the time of surgery and on the tumour's microscopic features, particularly how actively the cells are dividing.

Modified staging for canine renal tumours

Staged by local extent, vascular invasion, and distant metastasis

Stage LocalTumour confined to kidney without vascular invasion
Stage Locally advancedExtension into renal vein, perinephric tissue
Stage MetastaticDistant metastasis (pulmonary, hepatic, contralateral kidney, bone)
Prognostic Factors(2)
Mitotic indexStrongest prognostic factor. MI <10/10HPF: MST 40 months. MI >30/10HPF: MST 6 months. Critical data point for histopathology report.(Bryan et al., 2006)
Metastasis at diagnosisMetastatic disease at diagnosis significantly shortens survival. Non-metastatic: MST >4 years possible.(Bryan et al., 2006)
Minimum Workup(7 steps)
1Abdominal ultrasound (renal mass characterisation, contralateral kidney assessment)
2Abdominal CT (surgical planning, vascular invasion, staging)
3Thoracic radiographs (3-view) for pulmonary metastasis
4Complete blood count (polycythaemia as paraneoplastic — rare)
5Serum biochemistry including BUN/creatinine (contralateral kidney function)
6Urinalysis
7Regional lymph node assessment

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Nephrectomy
~16 mo (8–48)
Palliative / Supportive Care
~4 mo (1–8)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.